Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
or

Poseida Therapeutics Inc (PSTX)

Poseida Therapeutics Inc (PSTX)
9.50 -0.06 (-0.63%) 01/08/25 [NASDAQ]
N/A x N/A N/A x N/A
Realtime by (Cboe BZX)
N/A x N/A N/A x N/A
Realtime - - (-) -
Quote Overview for Tue, Jan 7th, 2025
Day Low
9.49
Day High
9.67
Open 9.58
Previous Close 9.56 9.56
Volume 21,420,600 21,420,600
Avg Vol 2,215,435 2,215,435
Stochastic %K 56.43% 56.43%
Weighted Alpha -2.36 -2.36
5-Day Change +0.02 (+0.21%) +0.02 (+0.21%)
52-Week Range 1.87 - 9.67 1.87 - 9.67
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 928,853
  • Shares Outstanding, K 97,774
  • Annual Sales, $ 64,700 K
  • Annual Income, $ -123,430 K
  • EBIT $ -63 M
  • EBITDA $ -64 M
  • 60-Month Beta 1.63
  • Price/Sales 6.08
  • Price/Cash Flow N/A
  • Price/Book 10.58
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.63
  • Most Recent Earnings $0.21 on 11/07/24
  • Next Earnings Date 03/06/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.40
  • Number of Estimates 2
  • High Estimate -0.29
  • Low Estimate -0.50
  • Prior Year -0.27
  • Growth Rate Est. (year over year) -48.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.35 +1.60%
on 12/09/24
Period Open: 9.36
9.67 -1.76%
on 01/07/25
+0.14 (+1.50%)
since 12/06/24
3-Month
2.32 +309.48%
on 10/31/24
Period Open: 2.66
9.67 -1.76%
on 01/07/25
+6.84 (+257.14%)
since 10/07/24
52-Week
1.87 +408.02%
on 04/16/24
Period Open: 3.17
9.67 -1.76%
on 01/07/25
+6.33 (+199.68%)
since 01/05/24

Most Recent Stories

More News
News Movers: Your Daily Digest of Stocks That Released News Which Moved the Market

SURG : 2.37 (+1.28%)
PSTX : 9.50 (-0.63%)
KULR : 1.2800 (-1.54%)
TOYO : 2.68 (-0.87%)
AVXL : 8.84 (-3.07%)
MAXN : 2.76 (-1.43%)
POET : 3.76 (-1.05%)
SAVA : 1.4000 (-2.10%)
Insider Sale: Executive Chairman of $PSTX (PSTX) Sells 30,000 Shares

Mark J Gergen, the Executive Chairman of $PSTX ($PSTX), sold 30,000 shares of the company on 11-26-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 4.4% of...

PSTX : 9.50 (-0.63%)
News Movers: Your Daily Digest of Stocks That Released News Which Moved the Market

WealthyVC.com scans North America’s 10,000+ publicly listed stocks across all seven exchanges to find the market-moving news that matters. Our focus is on quality, liquid, growth-oriented companies in...

SURG : 2.37 (+1.28%)
KULR : 1.2800 (-1.54%)
PSTX : 9.50 (-0.63%)
AVXL : 8.84 (-3.07%)
TOYO : 2.68 (-0.87%)
MAXN : 2.76 (-1.43%)
PTK.VN : 5.190 (-2.08%)
POET : 3.76 (-1.05%)
SAVA : 1.4000 (-2.10%)
Poseida Therapeutics Stock Hits Over 3-Year Highs On Roche’s $1.5B Buyout Deal: Retail Is Euphoric

The deal underscores Roche's interest in Poseida’s proprietary non-viral platform, which enables the development of allogeneic CAR-T therapies enriched with T stem cell memory cells.

PSTX : 9.50 (-0.63%)
RHHBY : 38.5800 (+0.21%)
MaxCyte Appoints Cynthia Collins to its Board of Directors

PSTX : 9.50 (-0.63%)
MXCN.LN : 680.000 (unch)
DMTKQ : 0.0001 (-99.00%)
MXCT.LN : 193.000 (-1.03%)
MXCT : 2.55 (-3.77%)
CERT : 13.53 (-2.52%)
Poseida Therapeutics Announces Leadership Transition

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...

PSTX : 9.50 (-0.63%)
Poseida Therapeutics Provides Financial Results for the Second Quarter of 2023

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...

PSTX : 9.50 (-0.63%)
Poseida Therapeutics Announces Strategic Investment by Astellas and Provides Business Update

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...

PSTX : 9.50 (-0.63%)
Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy

Poseida is a clinical-stage biotechnology company dedicated to advancing a new class of cancer cell therapy and gene therapy products using genetic engineering...

PSTX : 9.50 (-0.63%)
Poseida Therapeutics Announces Virtual 2023 Annual Meeting of Stockholders

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...

PSTX : 9.50 (-0.63%)
Poseida Therapeutics to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...

PSTX : 9.50 (-0.63%)
Poseida Therapeutics to Present at 31st Congress of the International Society on Thrombosis and Haemostasis

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...

PSTX : 9.50 (-0.63%)
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2023

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...

PSTX : 9.50 (-0.63%)
Poseida Therapeutics Announces Multiple Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...

PSTX : 9.50 (-0.63%)
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...

PSTX : 9.50 (-0.63%)
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2022

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...

PSTX : 9.50 (-0.63%)
Poseida Therapeutics Hosts Third Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...

PSTX : 9.50 (-0.63%)
Poseida Therapeutics Announces Board Change

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...

PSTX : 9.50 (-0.63%)
Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...

PSTX : 9.50 (-0.63%)
Poseida Therapeutics to Present Early Data from Phase 1 Trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO Immuno-Oncology 2022 Annual Congress

P-MUC1C-ALLO1 and P-BCMA-ALLO1 were well tolerated, with no dose-limiting toxicities (DLTs), cytokine release syndrome (CRS), graft vs host disease (GVHD) or...

PSTX : 9.50 (-0.63%)

Business Summary

Poseida Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing therapeutics for high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed...

See More

Key Turning Points

3rd Resistance Point 9.79
2nd Resistance Point 9.73
1st Resistance Point 9.62
Last Price 9.50
1st Support Level 9.44
2nd Support Level 9.38
3rd Support Level 9.26

See More

52-Week High 9.67
Last Price 9.50
Fibonacci 61.8% 6.69
Fibonacci 50% 5.77
Fibonacci 38.2% 4.85
52-Week Low 1.87

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro